Fisher & Paykel Healthcare Corporation Ltd

Fisher & Paykel Healthcare Corporation Ltd

  • Price (EUR)15.10
  • Today's Change0.10 / 0.67%
  • Shares traded0.00
  • 1 Year change-3.21%
  • Beta--
Data delayed at least 15 minutes, as of Mar 24 2023 15:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets medical device products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The Company offers its products across hospital and homecare settings. The Company’s hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, and laparoscopic and open surgery. Its homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home, which include the Company’s continuous positive airway pressure (CPAP) therapy masks, as well as flow generators, interfaces, and data management technologies. The Company operates across Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, India, Germany, Austria, Italy, Turkey, China, Hong Kong, Taiwan, Malaysia, Singapore and Australia.

  • Revenue in NZD (TTM)1.47bn
  • Net income in NZD251.00m
  • Incorporated1954
  • Employees7.38k
  • Location
    Fisher & Paykel Healthcare Corporation Ltd15 Maurice Paykel Place, East TamakiAUCKLAND 1061New ZealandNZL
  • Phone+64 95740100
  • Fax+64 95740158
  • Websitehttps://www.fphcare.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.